Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

NCT03719313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

407

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis Delta Virus

Interventions

DRUG: Lonafarnib
DRUG: Ritonavir
DRUG: PEG IFN-alfa-2a
DRUG: Placebo Lonafarnib
DRUG: Placebo Ritonavir

Sponsor

Eiger BioPharmaceuticals